• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1 Contact Hour(s)

    Release Date

    Thursday, October 31, 2019

    Offline Date

    Thursday, April 30, 2020

    ACPE Expiration Date

    Monday, October 31, 2022

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      This activity is designed to update pharmacists as to the new and exciting developments currently evolving in the area of nuclides and neuroendocrine neoplasms. This program will review the pathophysiology and clinical characteristics of GI NET and discuss unique concepts in patients with GI NET that influence treatment decisions. We will evaluate safety and efficacy by looking at clinical trial data for somatostatin analogues, everolimus, sunitinib, capecitabine/temozolomide, & lutetium-177 dotatate. This will highlight clinical application of the trial data for these therapies and will also review updates to the NCCN guidelines. We will discuss the role of theranostics with Ga-68 dotatate PET imaging in determining treatment eligibility for lutetium-177 dotatate while also reviewing pharmacology and supportive care concepts. Logistical considerations in implementing and growing a lutetium-177 dotatate therapy program will be discussed. Finally, we will discuss future treatment directions in patients with GI NET.

      Handouts

      • Slide Document :   ce_12_slides.pdf

      Financial Support By

      joint funding from Advanced Accelerator Applications, a Novartis Company, BMS and Pfizer Alliance, Celgene Corporation, Ipsen, Merck & Co., Inc, and Pfizer
    • Pharmacist

      Describe the complexities and intricacies involved with lutetium-177 dotatate therapy
      Recognize the role of current anticancer therapies in the management of gastrointestinal neuroendocrine tumors (GI NET)
      Recognize the evolving use of theranostics within GI NET

      Nurse

      Describe the complexities and intricacies involved with lutetium-177 dotatate therapy
      Recognize the evolving use of theranostics within GI NET
      Recognize the role of current anticancer therapies in the management of gastrointestinal neuroendocrine tumors (GI NET)
    • Activity Type

      Knowledge

      CE Broker

      20-747168

      Universal Activity Number

      Pharmacist 0798-0000-19-197-H01-P
      Nurse 0798-0000-19-197-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

    • Faculty

      Jon  Aston, PharmD, BCOP
      Clinical Pharmacy Specialist, GI Medical Oncology Clinic; Vanderbilt University Medical Center

    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).